Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 7/20 | 0.45 |
| ▸ | MMP3 | P08254 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14201498 | 1.00 | GRIK1 (0.50) | GRIK1POLBMMP2MMP3SMN1; SMN2 | |
| SCHEMBL14201454 | 0.95 | TRPA1 (0.48) | GRIK1POLBSMN1; SMN2HDAC3MAPK1 | |
| SCHEMBL14201456 | 0.90 | TSHR (0.45) | GRIK1SMN1; SMN2GRM2GRM3HIF1A | |
| SCHEMBL14259474 | 0.85 | GRIK1 (0.49) | GRIK1POLBMMP2MMP3TRPA1 | |
| SCHEMBL4737745 | 0.81 | GRIK1 (0.47) | GRIK1MMP2MMP3SMN1; SMN2HDAC3 | |
| SCHEMBL14145254 | 0.81 | GRIK1 (0.47) | GRIK1MMP2MMP3SMN1; SMN2HDAC3 | |
| SCHEMBL9620206 | 0.78 | TRPA1 (0.56) | POLBTRPA1 | |
| SCHEMBL14145666 | 0.78 | GRIK1 (0.43) | GRIK1POLBMMP2MMP3SMN1; SMN2 | |
| SCHEMBL27644145 | 0.78 | TSHR (0.49) | GRIK1SMN1; SMN2HIF1ACYP2D6KMT2A | |
| SCHEMBL27620462 | 0.76 | GRIK1 (0.48) | GRIK1POLBMMP2MMP3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008031032-A2 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | TRANSITION THERAPEUTICS INC. (CA) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096799-A1 | COMPOUNDS FOR AND METHODS OF TREATING INSULIN RESISTANCE AND INFLAMMATION | PNLIP, CPT1A, CPT1B | GRIK1 2010/4885POLB 2436/4885MMP2 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.